Preventing Asthma in High Risk Kids (PARK)

A double blinded four year study for children 24 - 47 months with the goal of identifying if injections of Omalizumab (Xolair) for two years, could prevent children from getting Asthma and lessen the severety of their breathing problems as they grow.

More information coming soon! 

Principal Investigator(s): 
Fernando Martinez, MD
Wayne Morgan, MD
Study Status: 
Currently Enrolling
Sponsor: 
National Institutes of Health (NIH)